68Ga-PSMA and 177Lu-PSMA of high specific activity for targeted diagnosis and therapy of prostate cancer in patients

Conclusion: The high specific activities required for the clinical application of these radiopharmaceuticals for prostate cancer diagnosis and therapy require careful control of the ratio activity/precursor as well as incubation temperature and time. 68Ga-PSMA of high RP and SA is being used in patients at our Centre with excellent results. 177Lu-PSMA is ready to start a pilot study with patients.

Source: Journal of Nuclear Medicine - May 24, 2017 Category: Nuclear Medicine Authors: Bentancor, N., Trindade, V., Vasilskis, E., Sanz, I., Balter, H., Engler, H. Tags: Radiopharmacy: Synthesis and Evaluation Source Type: research